ProCE Banner Activity

Blinatumomab After AlloHSCT in Patients With R/R B-Precursor ALL

Slideset Download
Conference Coverage
In a subanalysis of a phase II trial, patients with R/R B-precursor ALL after alloHSCT achieved a 45% CR/CRh rate with blinatumomab treatment.

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen